Song PF, Xu N, Li Q., et al. - In elderly patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), researchers assessed the safety and effectiveness of anlotinib as well as if common adverse reactions could act as prognosticators. Among 79 included elderly patients (≥ 60 years) with ES-SCLC who failed after at least two lines of previous systemic therapy, seven patients had partial response (PR), 48 patients exhibited stable disease (SD), and 24 patients had progressive disease. The objective response rate was 8.9%, the disease control rate was 69.6%, median progression-free survival was 3.0 months, and the median overall survival was 7.1 months. The common adverse reactions of these patients were hypertension (40.5%), hand-foot syndrome (HFS, 31.6%), diarrhea (27.8%), decreased appetite (20.3%), fatigue (17.7%) and weight loss (17.7%). The median PFS of patients with hypertension was 4.35 months while for those without hypertension it was 2.95 months; and the median PFS of patients with HFS was 4.20 and for those without HFS it was 2.95 months. Per findings, the preliminary safety and effectiveness of anlotinib in these patients was satisfactory. Patients with hypertension and hand-foot syndrome might have a better prognosis.